Roivant Sciences's three largest insider shareholders as of April 17, 2026 are Pharma Technologies Ltd. Dexcel (TenPercentOwner, 102.85Mn shares), Investments (Uk) Ltd Svf (TenPercentOwner, 73.03Mn shares), Investments (Uk) Ltd Svf (TenPercentOwner, 73.03Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Pharma Technologies Ltd. Dexcel | - | 102,849,443 | 0 | 14 Nov, 2022 |
| Investments (Uk) Ltd Svf | - | 0 | 73,031,667 | 02 Oct, 2023 |
| Investments (Uk) Ltd Svf | - | 0 | 73,031,667 | 02 Oct, 2023 |
| Chemical Co., Ltd. Sumitomo | - | 0 | 71,251,083 | 26 Jun, 2023 |
| Chemical Co., Ltd. Sumitomo | - | 0 | 71,251,083 | 26 Jun, 2023 |
| Daniel Allen Gold | - | 0 | 66,664,336 | 07 Mar, 2024 |
| Financial Lp Qvt | - | 0 | 65,178,939 | 02 Oct, 2023 |
| Vivek Ramaswamy | - | 33,653,755 | 0 | 15 Dec, 2025 |
| Keith S Manchester | - | 0 | 28,010,344 | 14 Nov, 2022 |
| Financial Lp Qvt | - | 0 | 19,311,790 | 07 Mar, 2024 |
| Mayukh Sukhatme | President Cio | 18,677,617 | 0 | 01 Apr, 2026 |
| Mayukh Sukhatme | President Cio | 18,677,617 | 0 | 01 Apr, 2026 |
| Matthew Gline | Ceo | 17,025,890 | 0 | 01 Apr, 2026 |
| Financial Lp Qvt | - | 0 | 15,127,329 | 13 Feb, 2026 |
| Daniel Allen Gold | - | 0 | 15,127,329 | 13 Feb, 2026 |
| Keith S Manchester | - | 0 | 15,127,329 | 13 Feb, 2026 |
| Frank Torti | President And Vant Chair | 13,576,512 | 0 | 02 Apr, 2026 |
| Vivek Ramaswamy | - | 0 | 13,357,857 | 27 Jan, 2025 |
| Global Investors Lp Viking | - | 0 | 12,884,307 | 26 Jun, 2023 |
| Global Investors Lp Viking | - | 0 | 12,884,307 | 26 Jun, 2023 |
| Global Performance Llc Viking | - | 0 | 12,884,307 | 26 Jun, 2023 |
| Global Performance Llc Viking | - | 0 | 12,884,307 | 26 Jun, 2023 |
| Keith S Manchester | - | 0 | 12,431,330 | 02 Oct, 2023 |
| Financial Lp Qvt | - | 0 | 10,033,908 | 27 Jun, 2025 |
| Daniel Allen Gold | - | 0 | 10,033,908 | 27 Jun, 2025 |
| Keith S Manchester | - | 0 | 10,033,908 | 27 Jun, 2025 |
| Daniel Allen Gold | - | 8,965,894 | 0 | 12 Sep, 2025 |
| Keith S Manchester | - | 1,948,403 | 0 | 12 Sep, 2025 |
| Daniel Allen Gold | - | 0 | 1,713,508 | 26 Sep, 2024 |
| Eric Venker | President Immunovant Ceo | 1,647,546 | 0 | 19 Mar, 2026 |
| Richard Pulik | Cfo | 236,867 | 0 | 24 Mar, 2026 |
| Rakhi Kumar | Chief Accounting Officer | 162,306 | 0 | 24 Feb, 2025 |
| Ilan Oren | - | 119,428 | 0 | 22 Jan, 2026 |
| James C Momtazee | - | 109,030 | 0 | 22 Jan, 2026 |
| Jennifer Humes | Chief Accounting Officer | 84,191 | 0 | 10 Apr, 2026 |
| Andrew Lo | - | 52,142 | 0 | 19 Sep, 2022 |
| Meghan Fitzgerald | - | 42,963 | 0 | 30 Mar, 2026 |
| Melissa B, Epperly | - | 15,804 | 0 | 18 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 08 Apr, 2026 | Jennifer Humes | Common Shares | D | 13,538 | $28.37 | 84,191 | D | S |
| 31 Mar, 2026 | Frank Torti | Common Shares | D | 160,035 | $27.70 | 13,576,512 | D | F |
| 30 Mar, 2026 | Matthew Gline | Common Shares | A | 97,319 | - | 17,384,400 | D | M |
| 30 Mar, 2026 | Mayukh Sukhatme | Common Shares | A | 58,391 | - | 18,894,938 | D | M |
| 30 Mar, 2026 | Mayukh Sukhatme | Common Shares | D | 29,809 | $26.41 | 18,865,129 | D | F |
| 30 Mar, 2026 | Matthew Gline | Common Shares | D | 53,826 | $26.41 | 17,330,574 | D | F |
| 31 Mar, 2026 | Mayukh Sukhatme | Common Shares | D | 187,512 | $27.70 | 18,677,617 | D | F |
| 31 Mar, 2026 | Matthew Gline | Common Shares | D | 304,684 | $27.70 | 17,025,890 | D | F |
| 30 Mar, 2026 | Mayukh Sukhatme | Capped Value Appreciation Rights | D | 1,306,889 | $11.50 | 0 | D | M |
| 30 Mar, 2026 | Matthew Gline | Capped Value Appreciation Rights | D | 2,178,150 | $11.50 | 0 | D | M |
| 26 Mar, 2026 | Meghan Fitzgerald | Common Shares | A | 70,000 | $8.80 | 112,963 | D | M |
| 26 Mar, 2026 | Meghan Fitzgerald | Common Shares | D | 70,000 | $27.45 | 42,963 | D | S |
| 26 Mar, 2026 | Meghan Fitzgerald | Stock Option (Right to Buy) | D | 70,000 | $0.00 | 48,578 | D | M |
| 20 Mar, 2026 | Richard Pulik | Common Shares | D | 1,546 | $27.70 | 236,867 | D | F |
| 20 Mar, 2026 | Jennifer Humes | Common Shares | D | 14,526 | $27.70 | 97,729 | D | F |
| 17 Mar, 2026 | Eric Venker | Common Shares | A | 200,000 | $3.85 | 1,847,546 | D | M |
| 17 Mar, 2026 | Eric Venker | Common Shares | D | 200,000 | $28.24 | 1,647,546 | D | S |
| 17 Mar, 2026 | Eric Venker | Stock Option (Right to Buy) | D | 200,000 | $0.00 | 4,844,834 | D | M |
| 16 Mar, 2026 | Melissa B, Epperly | Common Shares | D | 41,861 | $28.68 | 15,804 | D | S |
| 20 Feb, 2026 | Eric Venker | Common Shares | D | 7,051 | $27.15 | 1,647,546 | D | F |